# A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

> **NCT01045083** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 25 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** RO4917523
- **DRUG:** escitalopram
- **DRUG:** methylphenidate
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01045083
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01045083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01045083, "A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01045083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*